Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.93

-0.6%

Dec 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bio_kruncher who wrote (23797)	5/25/2007 3:37:32 PM
From: Arthur Radley	Read Replies (1) of 52153

WASHINGTON, May 25 (Reuters) - A U.S. Food and Drug Administration preliminary analysis found a level of heart-attack risk with GlaxoSmithKline Plc's (GSK.L: Quote, Profile , Research) (GSK.N: Quote, Profile , Research)diabetes drug Avandia similar to what was reported in a study earlier this week, the agency confirmed on Friday. FDA spokeswoman Julie Zawisza stressed that other data conflicted with that finding, and officials still were weighing whether to take any action. A Cleveland Clinic analysis released Monday said the drug increased the chances of having a heart attack by 43 percent.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next